Theravance Biopharma, Inc. Shareholders' Equity
Theravance Biopharma, Inc. (TBPH) had Shareholders' Equity of $289.70 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-11
- 2026-06-30: Stockholders' Equity Attributable to Parent $289.70M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $290.59M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $296.72M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $232.68M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $289.70M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $290.59M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $296.72M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $232.68M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $224.85M 10-Q · filed 2025-11-12 |
| 2025-03-31 | $165.98M 10-Q · filed 2025-08-13 |
| 2024-12-31 | $175.54M 10-K · filed 2026-03-23 |
| 2024-09-30 | $185.65M 10-Q · filed 2025-11-12 |
| 2024-06-30 | $193.69M 10-Q · filed 2025-11-12 |
| 2024-03-31 | $204.87M 10-Q · filed 2025-08-13 |
| 2023-12-31 | $213.00M 10-Q · filed 2025-11-12 |
| 2023-09-30 | $246.13M 10-Q · filed 2024-11-14 |
| 2023-06-30 | $280.16M 10-Q · filed 2024-11-14 |
| 2023-03-31 | $370.56M 10-Q · filed 2024-08-08 |
| 2022-12-31 | $441.80M 10-K · filed 2025-03-07 |
| 2022-09-30 | $480.58M 10-Q · filed 2023-11-09 |
| 2022-06-30 | -$349.81M 10-Q · filed 2023-11-09 |
| 2022-03-31 | -$351.45M 10-Q · filed 2023-08-09 |
| 2021-12-31 | -$338.57M 10-K · filed 2024-03-01 |
| 2021-09-30 | -$323.59M 10-Q · filed 2022-11-09 |
| 2021-06-30 | -$300.37M 10-Q · filed 2022-11-09 |
| 2021-03-31 | -$373.22M 10-Q · filed 2022-08-08 |
| 2020-12-31 | -$303.75M 10-K · filed 2023-03-01 |
| 2020-09-30 | -$261.54M 10-Q · filed 2021-11-08 |
| 2020-06-30 | -$202.34M 10-Q · filed 2021-11-08 |
| 2020-03-31 | -$157.94M 10-Q · filed 2021-08-05 |
| 2019-12-31 | -$223.84M 10-K · filed 2023-03-01 |
| 2019-09-30 | -$182.81M 10-Q · filed 2020-11-09 |
| 2019-06-30 | -$137.22M 10-Q · filed 2020-11-09 |
| 2019-03-31 | -$113.25M 10-Q · filed 2020-08-10 |
| 2018-12-31 | -$51.59M 10-K · filed 2022-02-28 |
| 2018-09-30 | -$13.45M 10-Q · filed 2019-11-08 |
| 2018-06-30 | $34.39M 10-Q · filed 2019-11-08 |
| 2018-03-31 | $63.41M 10-Q · filed 2019-08-05 |
| 2017-12-31 | $115.18M 10-K · filed 2021-02-26 |
| 2017-09-30 | $184.12M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $241.13M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $293.95M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $350.23M 10-K · filed 2020-02-27 |
| 2016-09-30 | $297.87M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $321.58M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $238.54M 10-Q · filed 2016-05-10 |
| 2015-12-31 | $243.06M 10-K · filed 2019-02-28 |
| 2015-09-30 | $222.54M 10-Q · filed 2015-11-12 |
| 2015-06-30 | $257.67M 10-Q · filed 2015-08-13 |
| 2015-03-31 | $289.12M 10-Q · filed 2015-05-13 |
| 2014-12-31 | $289.79M 10-K · filed 2018-02-28 |
| 2014-09-30 | $339.82M 10-Q · filed 2014-11-12 |
| 2014-06-30 | $384.76M 10-Q · filed 2014-08-14 |
| 2014-03-31 | -$17.92M 10-Q · filed 2014-06-24 |
| 2013-12-31 | -$17.04M 10-K · filed 2017-03-01 |
| 2012-12-31 | -$6.99M 10-K · filed 2016-03-11 |
| 2011-12-31 | -$140.72M 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |